...
首页> 外文期刊>Biochemical Pharmacology >Alpha anomer of 5-aza-2'-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells.
【24h】

Alpha anomer of 5-aza-2'-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells.

机译:5-氮杂-2'-脱氧胞苷的α异构体下调人白血病HL-60细胞中的hTERT mRNA表达。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

DNA methylation inhibitors are being extensively studied as potential anticancer agents. In the present study, we compared the capability of alpha anomer of 5-aza-2'-deoxycytidine (alpha-5-azadCyd) to induce down-regulation of hTERT expression in HL-60 cells with other nucleoside analogs that act as DNA methylation inhibitors: beta-5-azadCyd (decitabine), (S)-9-(2,3-dihydroxypropyl)adenine [(S)-DHPA], isobutyl ester of (R,S)-3-(adenin-9-yl)-2-hydroxypropanoic acid [(R,S)-AHPA-ibu] and prospective DNA methylation inhibitors (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine [(S)-HPMPazaC] and 5-fluoro-zebularine (F-PymRf). Exposure to alpha-5-azadCyd induced the down-regulation of hTERT expression in low micromolar concentrations (0.05-50 microM). A more cytotoxic beta anomer caused a transient up-regulation of hTERT and a subsequent reduction in hTERT mRNA levels at concentrations more than 10 times below its GIC50 value. In this respect, (S)-DHPA and (R,S)-AHPA-ibu were less efficient, since asimilar effect was achieved at concentrations above their GIC(50). In contrast, F-PymRf treatment resulted in up to a three-fold induction of hTERT expression within a broad range of concentrations. In all cases, the down-regulation of hTERT expression was concentration-dependent. The correlation was found between c-myc overexpression and transiently elevated hTERT expression after treatment with all tested compounds except for alpha-5-azadCyd and (S)-HPMPazaC. Although the primary task of hypomethylating agents in anticancer therapy lies in reactivation of silenced tumour-suppressor genes, the inhibition of hTERT expression might also be a fruitful clinical effect of this approach.
机译:DNA甲基化抑制剂作为潜在的抗癌剂已被广泛研究。在本研究中,我们将5-氮杂2'-脱氧胞苷(alpha-5-azadCyd)的α异头物与其他充当DNA甲基化作用的核苷类似物诱导HL-60细胞中hTERT表达下调的能力进行了比较。抑制剂:β-5-azadCyd(地他滨),(S)-9-(2,3-二羟丙基)腺嘌呤[(S)-DHPA],(R,S)-3-(腺嘌呤-9-基)的异丁酯)-2-羟基丙酸[(R,S)-AHPA-ibu]和预期的DNA甲基化抑制剂(S)-1- [3-羟基-2-(膦酰基甲氧基)丙基] -5-氮杂胞嘧啶[(S)-HPMPazaC ]和5-氟-zebularine(F-PymRf)。暴露于alpha-5-azadCyd会在低微摩尔浓度(0.05-50 microM)下诱导hTERT表达下调。具有更高细胞毒性的β端基异构体引起hTERT的瞬时上调,并导致其浓度低于其GIC50值10倍以上的hTERT mRNA水平降低。在这方面,(S)-DHPA和(R,S)-AHPA-ibu的效率较低,因为在高于其GIC(50)的浓度下可获得相似的效果。相反,F-PymRf处理可在很宽的浓度范围内引起hTERT表达的三倍诱导。在所有情况下,hTERT表达的下调都是浓度依赖性的。在用除α-5-azadCyd和(S)-HPMPazaC以外的所有测试化合物处理后,c-myc过表达与hTERT表达瞬时升高之间存在相关性。尽管低甲基化药物在抗癌治疗中的主要任务在于恢复沉默的肿瘤抑制基因,但抑制hTERT表达也可能是该方法的有效临床效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号